EUCTR2012-004025-24-GB进行中（未招募）1 期
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY(De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia) - DESTINY
niversity of Liverpool0 个研究点目标入组 174 人开始时间: 2013年6月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) CML in first chronic phase. 2) Demonstration of BCR-ABL1 positivity at or shortly after original diagnosis*. 3) Written Informed Consent 4) Must have received TKI treatment for at least 3 years. 5) At least 3 molecular results over the preceding 12 months, that fit either of the following groups (results from any UK lab are acceptable): a)(MR4 group) all the available BCR-ABL1 molecular results over the preceding 12 months are in MR4 (MR4 is defined as a BCR-ABL1/ABL1 ratio of zero, with at least 10,000 ABL1 control transcripts). b)(MMR group) some or all BCR-ABL1 molecular results are in MMR (BCR-ABL1/ABL1 ratio of 0.1% or less, but not zero, with at least 10,000 ABL1 control transcripts). If the results over the preceding 12 months are a mix of MMR and undetectable BCR-ABL1, then the patient is eligible for the MMR but not the MR4 group. * Patients who are Philadelphia chromosome (Ph) negative (or whose Ph status is not known) are eligible. Patients who do not have a standard BCR-ABL1 fusion transcript (i.e. other than e13a2 or e14a2, also known as b2a2 and b3a2) are eligible, but before screening the patient, contact should be made with Prof Foroni at Imperial College (see contacts) since specialised quantitative molecular assessment will be required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 68
排除标准
- •1)Age under 18 2)Life expectancy is predicted to be less than 37 months because of intercurrent illness 3)Presence of serious concomitant illness (e.g. heart, renal, respiratory or active malignant disease) that might preclude completion of the study 4)CML in accelerated phase or blast crisis at any time 5)Any molecular result during the preceding 12 months that is not in either MMR or MR4. 6)Treatment with higher than standard TKI doses (‘standard’ is defined as imatinib 400mg daily, nilotinib 400mg twice daily or dasatinib 100mg daily) 7)Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) twice or more because of intolerance. 8)Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) because of resistance. 9)Patients treated with lower than standard TKI doses (imatinib 400mg daily, nilotinib 400mg twice daily or dasatinib 100mg daily) for tolerance reasons may be included, but will de-escalate to the same doses as for standard dose patients and will be analysed separately, as they could be seen as undertreated. 10)Previous treatment with ponatinib or bosutinib. Patients who received interferon prior to commencing TKI (even if resistant to their interferon) are eligible, provided their response to TKI fits the entry criteria. 11)Pregnant or lactating women 12) Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.
研究者
相似试验
已完成
2 期
De-escalation and stopping treatment of imatinib, nilotinib or sprycel in chronic myeloid leukaemiaTopic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: Leukaemia (chronic)Chronic myelogenous leukaemiaCancerISRCTN74084226niversity of Liverpool (UK)168
已完成
4 期
A study on the procedure for treatment switch to epoetin beta pegol in the treatment of renal anemia in maintenance hemodialysis patientsRenal Anemia Patients on HemodialysisJPRN-UMIN000008090Faculty of medicine, University of Miyazaki30
已完成
3 期
Efficacy of WARTNER anti-wart local drug on genital wartsGenital wart.Anogenital (venereal) wartsIRCT138811073200N1Manoosha-Daru20
进行中（未招募）
1 期
Study on effectiveness of Flutiform® asthma inhalerMedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 16.1Level: PTClassification code 10038683Term: Respiratory disorderSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2013-005365-39-GBResearch in Real-Life Ltd224
进行中（未招募）
1 期
A randomised, controlled trial to compare the safety and effectiveness of steroid tape with silver nitrate therapy, the current standard treatment for patients who have over-granulating tissue of their periotoneal dialysis catheter exit site.Over-granulation of peritoneal dialysis exit site in patients with End Stage Renal FailureMedDRA version: 18.0 Level: PT Classification code 10034660 Term: Peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: LLT Classification code 10008831 Term: Chronic ambulatory peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: LLT Classification code 10067974 Term: Automated peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: PT Classification code 10067594 Term: Peritoneal dialysis complication System Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 18.0 Level: LLT Classification code 10064116 Term: Continuous ambulatory peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-003867-76-GBniversity Hospitals Birmingham NHS Foundation Trust80